In case you missed it amid all the talk about Obamacare and patent expirations, big pharma standout Pfizer (PFE) has tacked on 50% gains in the last five years to outperform the S&P handily.
Part of that is because of big efficiencies and a pop to the product pipeline after the 2009 acquisition of rival Wyeth for a jaw-dropping $68 billion. But it’s also thanks to an aggressive rethinking of the company structure via layoffs, marketing and research that puts an emphasis on the future.
Consider that this year Pfizer took the unusual step of selling erectile dysfunction drug Viagra directly to consumers via the Internet as an effort to get in front of drug counterfeiters! This clearly is a company thinking about its future.
And with a nice dividend and a recession-proof business model (consumers will cut out just about anything before they stop taking their pills), investors can be confident investing in Pfizer for the long haul.